IR-Med
Manufacturing · Israel · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Z.h.r Industrial Zone 20 Yahalom St, Ros...Phone Number
+972 46555054Website
www.ir-medical.comRevenue
-Stock Symbol
IRMEIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About IR-Med
IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company’s AI process to provide healthcare professionals with decision support in the detection and monitoring of various disease conditions.Explore more
IR-Med Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is IR-Med your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on IR-Med recently announced quarterly report
Product Launch: Get notified when IR-Med launches new products
Congratulate Masked Content for being promoted to Masked Content at IR-Med
IR-Med, which may be a good buyer, showed buying intent in Masked Content Topic
Check if IR-Med has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if IR-Med had a recent Job posting/layoffs
Funding: Get notified immidiatlly once IR-Med has new funding data
Website visits: Recent activity has been detected on your website
Check out if IR-Med is spiking on competitors!
Recommended Actions
Find VP level buyers at IR-Med
Find 3 more new buyers
Company Profile Activity
Activity Insights
IR-Med is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
IR-Med is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about IR-Med.
IR-Med financials insights
Gather financial insights about IR-Med, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Share Placement
$3.2M
IR-Med Tech Stack
A closer look at the technologies used by IR-Med
See more technologies
Most Recent Scoops
Initial Public Offering (IPO)
Project
Engineering, Product Management, Intellectual Property
Lateral Move
Executive Move
New Hire
Executive Move
Lateral Move
Executive Move
IR-Med News & Media
IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI ...
DiaSafe™, IR-MED's second product, is being developed to provide safe, real-time optical readings of biomarkers for assessment of diabetic foot ulcers The most common cause of amputation, diabetic foot ulcers can be prevented with early assessment, improving patient care and healthcare economics in a $10 billion global treatment market $500,000 grant underscores continued confidence in IR-MED's noninvasive "Sensing the Invisible" technology platformRosh Pina, Israel--(Newsfile Corp. - May 5, 202IR-MED CEO Issues Letter to Shareholders: Expanding Our Platform and Presenting New Clinical Data from Israel and the U.S.
Rosh Pina, Israel, March 18, 2025 (GLOBE NEWSWIRE) -- IR-MED Inc. (“IR-MED” or the “Company”) (OTCQB: IRME), a developer of noninvasive, AI-driven spectrographic analysis technology addressing significant healthcare needs, is pleased to share the following shareholder update from its Chief Executive Officer, Mr. Ran Ziskind.Methodist Healthcare Adopts IR-MED’s PressureSafe™ Device for Usability Study: Decision Support Device Aims to Reduce Substantial Healthcare Burden of Pressure Injuries
Rosh Pina, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, announced today the start of a usability study for its lead product, PressureSafe™, at San Antonio, Texas based Methodist Healthcare. The study, titled “Safety and Efficacy of the PressureSafe Device for Early Detection of Pressure Injury in PIR-MED Appoints Ran Ziskind, Tech Entrepreneur, Growth Manager, and Inventor as Chief Executive Officer
Rosh Pina, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, announced today that Mr. Ran Ziskind has joined the Company as Chief Executive Officer (CEO), effective September 1, 2024. Mr. Ronnie Klein, who had been serving as Interim CEO, continues to serve as the Company’s Chief Technology Officer.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding IR-Med
Sign Up For FreeTo access detailed company insights
IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company’s AI process to... Read More
